Investor Relations Corporate ProfileAssembly Bio aspires to deliver innovative small molecule antiviral therapeutics designed to change the path of serious viral and liver diseases and improve the lives of patients worldwide. Minimum 15 minutes delayed. Source: LSEG Press Releases See all news Assembly Biosciences to Participate in Upcoming Investor Conferences Assembly Biosciences Doses First Two Participants in Phase 2 Study of Oral NTCP Inhibitor ABI-6250 for Chronic Hepatitis Delta Virus Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026 Events & Presentations See all upcoming events Nov 17, 2026 2026 Jefferies Global Healthcare Conference Nov 16, 2026 at 12:00 PM GMT UBS Global Biopharma Conference Nov 10, 2026 at 2:00 PM EST Guggenheim 3rd Annual Healthcare Innovation Conference Shareholder Tools Print Email Alerts RSS News Feeds Search Investors
Investor Relations Corporate ProfileAssembly Bio aspires to deliver innovative small molecule antiviral therapeutics designed to change the path of serious viral and liver diseases and improve the lives of patients worldwide. Minimum 15 minutes delayed. Source: LSEG Press Releases See all news Assembly Biosciences to Participate in Upcoming Investor Conferences Assembly Biosciences Doses First Two Participants in Phase 2 Study of Oral NTCP Inhibitor ABI-6250 for Chronic Hepatitis Delta Virus Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026 Events & Presentations See all upcoming events Nov 17, 2026 2026 Jefferies Global Healthcare Conference Nov 16, 2026 at 12:00 PM GMT UBS Global Biopharma Conference Nov 10, 2026 at 2:00 PM EST Guggenheim 3rd Annual Healthcare Innovation Conference
